Session	Start-ups/SMEs looking for Finance: Series A and Series B/C Funding
Title	Delivering breakthrough biotechnology at scale to advance health
Company	Inbiose
Speaker	Joeri Beauprez
TRL	
Keywords feedstock (max 2)	Plain sugar
Keywords technology (max 2)	Precision fermentation, synthetic biology
Keywords End-Product (max 2)	Human milk oligosaccharide, OptiHMO

Abstract:

Human milk oligosaccharides (HMOs) are the third most abundant solid component of breast milk. Infant formula is moving from a single HMO, 2'-FL, to five-HMO blends, and the next step is formulas closer to the full complexity of human milk. Multi-HMO supply is dominated by two large incumbents.

Inbiose (Ghent, BE) makes HMOs by precision fermentation, with its own strains, processes and IP. Its flagship product 2'-FL is produced at infant grade at 120 m3 commercial scale and sold to customers, and the company holds EU and US clearances for six infant-formula HMOs. 3'-SL, 6'-SL, LNT, LNnT and 3-FL are moving to infant grade, enabling a five/six-HMO combination. We have launched the same products already in animal nutrition since 2023. Production is capital-light, as we run at contract manufacturers.

Our key differentiator is OptiHMO: a protected technology that makes more than 20 HMOs in a single strain, in ratios close to human milk, targeting super-premium formula from 2029 onwards. In addition, we also have several strategic joint development agreements with large industrial groups.

We are looking for investors and strategic partners to further scale and roll out our multi-HMO portfolio and bring OptiHMO to market, and for partners in feed and new bio-based applications of HMOs.